Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients - PubMed
3 hours ago
- #Neurologic Toxicity
- #BCMA CAR T
- #Multiple Myeloma
- BCMA-directed CAR T therapies significantly improve outcomes for relapsed or refractory multiple myeloma patients.
- Non-ICANS neurologic toxicities (NINTs) are poorly defined, with limited data on incidence and risk factors.
- A systematic review and meta-analysis of 55 cohorts involving 4,630 patients found a pooled NINT incidence of 0.81%.
- NINT incidence varies by product; cilta-cel has a significantly higher rate compared to ide-cel (4.6% vs. 0.5%).
- Meta-regression identified cilta-cel as independently associated with increased NINT risk compared to ide-cel.
- Cranial nerve palsies are the most common NINT phenotype (32.3% of events), followed by movement/neurocognitive issues and peripheral neuropathies.
- NINTs are rare but important toxicities, especially with cilta-cel, requiring standardized definitions and improved reporting for better risk characterization.